Education
About Us
Working with TipRanks
Follow Us
Feedback PLC (GB:FDBK)
LSE:FDBK
FDBK Stock Chart & Stats
9.25p
-0.50p(-2.47%)
At close: 4:00 PM EST
9.25p
-0.50p(-2.47%)
Day’s Range― - ―
52-Week Range7.50p - 19.00p
Previous CloseN/A
Volume41.00K
Average Volume (3M)76.45K
Market Cap
£4.71M
Enterprise Value-1.24M
Total Cash (Recent Filing)£3.82M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.07
Next Earnings
Sep 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding43,814,777
10 Day Avg. Volume152,066
30 Day Avg. Volume76,453
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.67
Price to Sales (P/S)4.70
P/FCF Ratio-1.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt capital structure materially reduces refinancing and interest-rate risk, giving management time and optionality to address operational weakness. Over 2–6 months this provides durable financial flexibility to raise equity or invest in product/Go-to-Market without near-term covenant pressure.
High Gross MarginsAn ~88% gross margin indicates the product has low incremental costs and strong unit economics typical of SaaS clinical software. If fixed operating costs are reined in, this margin profile supports durable operating leverage and scalability as sales recover, improving potential path to sustainable profitability.
Recurring SaaS Licensing ModelA recurring license/subscription model to hospitals creates sticky, predictable revenue and upsell potential with integrated deployments. Structurally this supports long-term customer retention and revenue visibility versus one-off services, enabling durable cash-flow improvement if sales traction returns.
Bears Say
Sharp Revenue DeclineA ~26% top-line decline signals demand or retention deterioration in core hospital customers. Persisting revenue contraction undermines operating leverage, makes fixed-cost absorption harder, and lengthens runway to breakeven; absent sustainable revenue recovery, long-term viability is strained.
Very Large Operating LossesNet margin near -826% reflects losses vastly exceeding tiny revenue, indicating current cost base is incompatible with scale. Large operating deficits erode equity, limit reinvestment in product and sales, and require ongoing financing—weakening the company’s durable ability to compete.
Persistent Negative Free Cash FlowConsecutive negative operating and free cash flows (~-2.8m latest) show the business cannot self-fund growth or losses. Persistent cash burn forces reliance on external capital, raising dilution and execution risk, and restricts strategic choices like sales investment or product expansion over the medium term.
Feedback News
FDBK FAQ
What was Feedback PLC’s price range in the past 12 months?
Feedback PLC lowest share price was 7.50p and its highest was 19.00p in the past 12 months.
What is Feedback PLC’s market cap?
Feedback PLC’s market cap is £4.71M.
When is Feedback PLC’s upcoming earnings report date?
Feedback PLC’s upcoming earnings report date is Sep 23, 2026 which is in 217 days.
How were Feedback PLC’s earnings last quarter?
Feedback PLC released its earnings results on Feb 17, 2026. The company reported -0.04p earnings per share for the quarter, missing the consensus estimate of N/A by -0.04p.
Is Feedback PLC overvalued?
According to Wall Street analysts Feedback PLC’s price is currently Overvalued.
Does Feedback PLC pay dividends?
Feedback PLC does not currently pay dividends.
What is Feedback PLC’s EPS estimate?
Feedback PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Feedback PLC have?
Feedback PLC has 43,814,777 shares outstanding.
What happened to Feedback PLC’s price movement after its last earnings report?
Feedback PLC reported an EPS of -0.04p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.321%.
Which hedge fund is a major shareholder of Feedback PLC?
Currently, no hedge funds are holding shares in GB:FDBK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Feedback PLC
Feedback plc, a medical imaging technology company, provides software and systems to those working in the field of medical imaging. Its products include TexRAD, a patent-protected software tool, which extracts and quantifies texture features in radiological images, assists research into all tumour types, and uncovers biomarkers in medical images; and TexRAD Lung, a software tool for the analysis of lung cancer for clinical use in the European Union. The company also offers Cadran image platform that provides hospitals and research institutes with a comprehensive picture archiving communication system for medical images, as well as equips users with a platform for image handling from all imaging modalities, such as CT and PET scanners; and Bleepa, a secure clinical communications platform that facilitates the sharing of clinical-grade medical images. Feedback plc was incorporated in 1958 and is headquartered in London, the United Kingdom.
Technical Analysis
Options Prices
Currently, No data available
---